Article Abstract

Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?

Authors: Wolfram C. M. Dempke, Klaus Fenchel


Over 70% of all non-small cell lung cancer (NSCLC) patients present with advanced or metastatic tumours at the time of diagnosis. Locally advanced (stage III) NSCLC is an important and controversial treatment subgroup comprising 25–30% of all NSCLC at diagnosis (1). Within this patient population, there is a considerable heterogeneity in both, tumour burden and the extent of lymph node involvement.